What is the mechanism of action of Selumetinib?

Selumetinibis aMEK 1/2 inhibitor for the treatment of symptomatic, inoperable plexiform neurofibromatosis (PN) type 1 (NF1) in pediatric patients.

It is known that the Ras-Raf-MEK-ERKsignaling cascade is activated in several types of cancer and regulates the transcription of proteins involved in apoptosis. Additionally, research suggests that mutations in theRaf component of this pathway may lead to resistance to chemotherapy drugs. Rasand several kinases and phosphatases are responsible for regulating the Raf-MEK-ERK pathway. Typically in cancer, Ras (aGprotein-coupled receptor) is deregulated, allowing downstream signaling to proceed uninhibited. Through several complex steps, Rafphosphorylates and activates MEK, which MEK then phosphorylates and activates ERK. ERKis then able to act on several downstream targets. Therefore, therapies that inhibit upstream components of this pathway have become attractive targets for cancer treatment. Selumetinib exerts its effects by selectively inhibiting MEK1 and MEK2, which effectively attenuates the pleiotropic effects of the Ras-Raf-MEK-ERK cascade. By inhibiting this oncogenic pathway, selumetinib reduces cell proliferation and promotes pro-apoptotic signaling.

Selumetinib is characterized by a short half-life. The elimination half-life in pediatric patients at a dose of 25mg/ cubic meters is 6.2 hours. In a study looking at the pharmacokinetic effects of different selumetinib regimens in selected Japanese patients, the half-life was 9.2- 10.6 hours. In other studies, 75 mg selumetinib was administered twice daily., the half-life is reported to be approximately13 hours. There is an original research version of selumetinib overseas, with a retail price of 10mg60 tablets50,000around. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.